Press Release Details

Cerus Corporation to Hold Conference Call to Discuss Corporate Update

June, 26 2007

CONCORD, Calif.--(BUSINESS WIRE)--June 26, 2007--Cerus Corporation (NASDAQ:CERS) announced today that company management will host an investment community conference call beginning at 4:30 p.m. EST on Tuesday, June 26, 2007, to discuss the French tender award announced earlier today and other corporate news.

To access the webcast via the internet, log on to www.cerus.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software downloads. Alternatively, you may access the live conference call by dialing 800-510-0219 (U.S.) or 617-614-3451 (International) and dial participant passcode 92481931. A telephone replay will be available approximately two hours after the call through 5:00 p.m. EST, July 3, 2007. To access the replay, please call 888-286-8010 (U.S.) or 617-801-6888 and enter passcode 98235978. The webcast will be archived on www.cerus.com through July 3, 2007.

ABOUT CERUS

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy designed to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology. The system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in the research and development of prophylactic and therapeutic vaccines for infectious diseases.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations

SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600